24567
document
An open multicenter efficacy and safety evaluation of amlodipine in the treatment of symptomatic myocardial ischemia . The efficacy and safety of amlodipine ( 5-10 mg ) once daily were studied in an open study in patients with symptomatic myocardial ischemia . The study is ongoing and this report is based on an interim analysis of data from 78 patients . A 2-week baseline period in which patients maintained their current antianginal therapy was followed by a 10-week treatment period with 5-10 mg of amlodipine/day . Both the median number of angina attacks per week and the median number of nitroglycerin ( NTG ) tablets consumed/week were significantly reduced after amlodipine ( mean daily dose of 8.6 mg ) when compared with baseline ( p < 0.05 ) . A total of 98.4 % of patients ( 63/64 ) experienced a reduction in the frequency of angina attacks/week and 91 % of patients ( 58/64 ) had angina attacks reduced to < or = 2/week . In self-assessments , 95 % of patients ( 55/58 ) reported improved angina control and 91 % ( 53/58 ) felt their ability to perform usual activities had improved . Twenty-seven patients experienced adverse events reported as drug related . The most common adverse event noted was edema . Amlodipine once daily significantly reduced the incidence of angina attacks and the concomitant need of nitroglycerin for relief of symptoms and thus improved the patients ' ability to perform daily activities . Most adverse events reported were mild or moderate and the incidence is as would be expected in this patient population .
24568
Intervention_Pharmacological
amlodipine
24569
Intervention_Pharmacological
amlodipine
24570
Intervention_Control
antianginal therapy
24571
Intervention_Pharmacological
amlodipine/day
24572
Intervention_Pharmacological
nitroglycerin
24573
Intervention_Pharmacological
amlodipine
24574
Intervention_Pharmacological
Amlodipine
24575
Intervention_Pharmacological
nitroglycerin
24576
Outcome_Other
efficacy and safety evaluation
24577
Outcome_Other
efficacy and safety
24578
Outcome_Physical
median number of angina attacks per week and the median number of nitroglycerin ( NTG ) tablets consumed/week
24579
Outcome_Physical
frequency of angina attacks/week
24580
Outcome_Physical
angina attacks
24581
Outcome_Physical
angina control
24582
Outcome_Physical
ability to perform usual activities
24583
Outcome_Adverse-effects
adverse events
24584
Outcome_Adverse-effects
adverse event
24585
Outcome_Adverse-effects
edema
24586
Outcome_Physical
incidence of angina attacks